Interpace Biosciences, Inc. (IDXGD)
OTCMKTS · Delayed Price · Currency is USD
6.91
+0.40 (6.18%)
At close: Sep 4, 2026
Interpace Biosciences Revenue
Interpace Biosciences had revenue of $9.13M in the quarter ending June 30, 2026, a decrease of -1.09%. This brings the company's revenue in the last twelve months to $36.14M, down -20.48% year-over-year. In the year 2025, Interpace Biosciences had annual revenue of $38.73M, down -17.47%.
Revenue (ttm)
36.14M
Revenue Growth
-20.48%
P/S Ratio
1.06
Revenue / Employee
354.35K
Employees
102
Market Cap
38.30M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 38.73M | -8.20M | -17.47% |
| Dec 31, 2024 | 46.93M | 6.89M | 17.21% |
| Dec 31, 2023 | 40.04M | 8.20M | 25.75% |
| Dec 31, 2022 | 31.84M | -1.28M | -3.86% |
| Dec 31, 2021 | 33.12M | 719.00K | 2.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jones Soda Co. | 38.78M |
| Koil Energy Solutions | 31.02M |
| First Community Financial | 23.14M |
| Enterprise Financial Services Group | 19.99M |
| TriLinc Global Impact Fund, LLC | 14.44M |
| Alpha One | 3.72M |
| Victor Mining Industry Group | 1.58M |
| Growth Stalk Holdings | 583.34K |
Interpace Biosciences News
- 9 days ago - Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting - GlobeNewsWire
- 3 months ago - Interpace Biosciences Announces First Quarter 2026 Financial and Business Results - GlobeNewsWire
- 5 months ago - Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results - GlobeNewsWire
- 5 months ago - Interpace Biosciences Earnings release: Q4 2025 - Filings
- 9 months ago - Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners - GlobeNewsWire
- 9 months ago - Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results - GlobeNewsWire
- 11 months ago - Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting - GlobeNewsWire
- 1 year ago - Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire